About one in four U.S. adults have nonalcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic ...

It is therefore not surprising that a number of bile-acid-activated signalling pathways have become attractive therapeutic targets for metabolic disorders. Here, we review how the signalling ...